Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 15/20 | 0.59 |
| ▸ | JAK3 | P52333 | 4/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1581282 | 0.92 | JAK2 (0.58) | JAK2JAK3KCNH2IKBKB | |
| SCHEMBL1893925 | 0.89 | JAK2 (0.57) | JAK2JAK3KCNH2IKBKB | |
| SCHEMBL1579871 | 0.88 | JAK2 (0.54) | JAK2JAK3KCNH2IKBKB | |
| SCHEMBL1579545 | 0.87 | JAK2 (0.56) | JAK2JAK3KCNH2IKBKB | |
| SCHEMBL1579514 | 0.87 | JAK2 (0.56) | JAK2JAK3KCNH2IKBKB | |
| SCHEMBL1891070 | 0.87 | JAK2 (0.54) | JAK2JAK3KCNH2IKBKB | |
| SCHEMBL1579437 | 0.86 | JAK2 (0.53) | JAK2JAK3KCNH2 | |
| SCHEMBL1579834 | 0.86 | JAK2 (0.53) | JAK2JAK3KCNH2IKBKB | |
| SCHEMBL1579538 | 0.86 | JAK2 (0.53) | JAK2JAK3KCNH2IKBKB | |
| SCHEMBL1579165 | 0.86 | JAK2 (0.55) | JAK2JAK3KCNH2IKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420695-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-04-16 | — | — | US | claimed |
| US-20110112081-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-05-12 | — | — | US | claimed |
| US-8420695-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420695-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-04-16 | — | — | US | disclosed |
| US-8420695-B2 | Inhibitors of janus kinases | MERCK SHARP & DOHME CORP. (US) | 2013-04-16 | — | — | US | disclosed |
| US-20110112081-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110112081-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-05-12 | — | — | US | disclosed |
| US-20110112081-A1 | INHIBITORS OF JANUS KINASES | MERCK SHARP & DOHME LLC | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112081-A1 | INHIBITORS OF JANUS KINASES | JAK2, JAK3, JAK1 | JAK2 1/4885JAK3 2/4885KCNH2 2508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.